Glyceryl trinitrate (GTN)
Brand names: GTN spray, Nitrolingual, Transiderm-Nitro, Rectogesic
Glyceryl trinitrate (GTN) is a short-acting nitrate vasodilator used for acute relief and prophylaxis of angina and, intravenously, for acute heart failure, pulmonary oedema and hypertensive emergencies.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is metabolised to nitric oxide, which raises vascular smooth-muscle cyclic GMP to cause vasodilatation, predominantly venous, reducing cardiac preload and myocardial oxygen demand and relieving coronary spasm.
Prescribing in practice
- It is contraindicated with phosphodiesterase-5 inhibitors such as sildenafil because the combination can cause profound, life-threatening hypotension.
- Sublingual tablets and sprays act within minutes for acute angina; if chest pain is not relieved after repeated dosing, emergency help should be sought as this may indicate myocardial infarction.
- Continuous nitrate exposure causes tolerance, so a nitrate-free interval is needed with longer-acting use, and abrupt withdrawal of intravenous nitrate should be avoided.
Monitoring
With intravenous use monitor blood pressure and heart rate closely; for oral and sublingual use review symptom control and tolerance.
Counselling the patient
- Sit down before using a sublingual dose as it can cause headache and dizziness.
- Never use with erectile-dysfunction medicines such as sildenafil.
- If angina is not relieved after repeated doses, call emergency services.
Evidence & guidelines
Sublingual and intravenous GTN are long-standing guideline-recommended treatments for angina and acute cardiogenic pulmonary oedema.
Reference: ESC ACS guidelines; NICE NG106; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines